Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
B.1.1.229NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.594NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.113NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.6.3NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.205NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.329NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.434NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.483NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.4.5NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.258.9NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.181NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.328NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.110NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.185NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BE.4NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.2.24NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.2.3.11NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.2.3.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-820.864US
BE.1.1.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-1549.93US
BA.5.1.24NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-4388.79US
BM.3NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.2.12NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.2.85NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-18328.8US
BA.5.1.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-820.864US
XATNSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.2.65NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-820.864US
BF.28NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-630.996US
BA.5.1.3NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-4388.79US
BA.2.13.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-4388.79US
BA.5.1.16NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BG.5NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-630.996US
BA.2.74NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-820.864US
BA.5.8NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-820.864US
BA.2.3.18NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-820.864US
BA.2.61NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-820.864US
BA.5.2.24NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-820.864US
BA.2.51NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-820.864US
BA.5.2.62NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-820.864US
BA.5.2.26NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BF.8NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-820.864US
BA.5.2.28NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.5.2.43NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BN.1.3.7NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
L.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.5.2.19NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
CH.1.1.24NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.96NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
AY.29 (Delta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BF.38.3NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-820.864US
BF.7.19.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used